Nuevocor Secures $45 Million Series B Funding to Advance Novel Cardiomyopathy Therapies

SINGAPORE and PHILADELPHIA – May 6, 2025 – Nuevocor, a biotechnology company based in Singapore advancing innovative treatments for cardiomyopathies stemming from irregular mechanobiology, today announced the successful completion of a US$45 million Series B financing round. The investment was jointly led by Kurma Partners and Angelini Ventures, with significant contributions from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund, as well as Highlight Capital and SEEDS Capital. In conjunction with this financing, Nuevocor welcomes Amanda Gett-Chaperot, PhD (Kurma Partners), and Elia Stupka, PhD (Angelini Ventures), to its Board of Directors.

The newly secured capital will support the initiation of a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 clinical trial of Nuevocor’s lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy (LMNA DCM). Clinical trial sites will be established across the U.S. and Europe. Furthermore, the company will expand its global footprint by establishing an office in Paris, France, to facilitate clinical development and bring Singaporean innovation to patients worldwide.

LMNA DCM is a genetic heart condition resulting from mutations in the LMNA gene, leading to the weakening and enlargement of the heart muscle and a rapid progression towards end-stage heart failure. It is estimated to affect over 100,000 individuals in the U.S. and Europe. NVC-001 and other assets in Nuevocor’s pipeline are derived from the company’s proprietary PrOSIA™ mechanobiology platform, which identifies the fundamental functional causes of various cardiomyopathies.

“We are thrilled to have achieved this significant financing milestone, enabling us to build a global company with such a strong and experienced syndicate of international life science investors,” said Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor. “The continued robust support from our existing investors, coupled with the addition of these new partners, will allow Nuevocor to maintain its strong momentum and advance NVC-001 into clinical trials. This exemplifies how Singapore is driving transformative innovation for patients globally.”

Dr. Amanda Gett-Chaperot, Partner at Kurma Partners, commented, “Nuevocor offers new hope to a substantial population of cardiovascular patients who currently lack effective treatment options by directly addressing the underlying causes of their disease. Recognizing the significant burden of cardiomyopathies, Kurma is excited to invest in Nuevocor through our new Biofund IV to create meaningful value by treating these critical conditions.”

Dr. Elia Stupka, Managing Director at Angelini Ventures, added, “Our investment in Nuevocor represents a strategic expansion for Angelini Ventures into cardiovascular disease, gene therapy, and the Singapore biotech ecosystem. We are particularly excited by Nuevocor’s innovative approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways, rather than solely focusing on gene replacement. This potential one-time therapy has the capacity to transform patient outcomes and alleviate healthcare burdens. We are proud to support their mission and join the Board, alongside Kurma, ClavystBio, EDBI, Boehringer Ingelheim Venture Fund, and other investors, as the company expands its global presence, including into Europe.”

About NVC-001:

NVC-001 is a first-in-class, AAV-based gene therapy candidate under development for the treatment of LMNA-related dilated cardiomyopathy (LMNA DCM), a particularly aggressive form of DCM characterized by rapid progression to end-stage heart failure and an increased risk of sudden cardiac death due to malignant ventricular arrhythmias. LMNA DCM is estimated to affect over 100,000 patients in the U.S. and Europe. NVC-001 is designed to reduce forces on the nucleus to restore nuclear envelope integrity, a key characteristic of LMNA DCM, thereby treating the disease. Preclinical studies have demonstrated significant survival benefits, high transduction levels, and a favorable safety profile for NVC-001 in both GLP toxicology studies and large animal models. Nuevocor anticipates initiating a Phase 1/2 clinical trial in early 2026, with trial sites in the U.S. and Europe, alongside a concurrent natural history study.

About Nuevocor:

Nuevocor is an IND-stage biotechnology company focused on developing novel therapies for genetic cardiomyopathies driven by irregular mechanobiology. Headquartered in Singapore, with an office in the U.S. and expanding into Europe, Nuevocor’s unique approach, powered by its proprietary PrOSIA™ mechanobiology platform, overcomes the limitations of traditional gene replacement therapy – which addresses individual gene mutations – by targeting defects in shared disease pathways across multiple cardiomyopathies, thereby addressing the fundamental cause of disease. Nuevocor is pioneering treatments for genetic cardiomyopathies that are not amenable to gene replacement therapy and currently lack effective treatment options.